BNT162b2 Vaccine Booster and Mortality Due to Covid-19 | Zendy

Ronen Arbel | Zendy; Ariel Hammerman | Zendy; Ruslan Sergienko | Zendy; Michael Friger | Zendy; Alon Peretz | Zendy; Doron Netzer | Zendy; Shlomit Yaron | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Author(s) -

Ronen Arbel,

Ariel Hammerman,

Ruslan Sergienko,

Michael Friger,

Alon Peretz,

Doron Netzer,

Shlomit Yaron

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2115624

Subject(s) - medicine , booster (rocketry) , covid-19 , virology , medline , coronavirus infections , booster dose , pandemic , betacoronavirus , infectious disease (medical specialty) , outbreak , disease , titer , political science , law , virus , physics , astronomy

The emergence of the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine (Pfizer-BioNTech) led to a resurgence of coronavirus disease 2019 (Covid-19) cases in populations that had been vaccinated early. On July 30, 2021, the Israeli Ministry of Health approved the use of a third dose of BNT162b2 (booster) to cope with this resurgence. Evidence regarding the effectiveness of the booster in lowering mortality due to Covid-19 is still needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research